Advanced searches left 3/3

Prostate Cancer - Europe PMC

Summarized by Plex Scholar
Last Updated: 24 April 2022

* If you want to update the article please login/register

Androgen deprivation therapy and depression in the prostate cancer patients: review of risk and pharmacological management.

Despite the effectiveness of androgen deprivation therapy in advanced prostate cancer, severe neuropsychiatric risks in androgen deprivation therapy-treated patients, mostly depression, have been troubling and gained more attention lately. According to each, although several drugs have been used for depression in cancer patients, current research lacks observational and controlled studies, as well as clinical guidelines that establish the effectiveness and safety of antidepressants and guide clinicians to the correct treatment for those patients. Other ADT-related adverse effects have been published on several research findings including selective serotonin reuptake inhibitors, selective serotonin, and nominectomy saftey. The foundation that can be used to test these medications on ADT-induced depression was published in clinical trials involving the use of antidepressants for other ADT-related adverse effects.

Source link: https://europepmc.org/article/MED/35343371


Bone-targeted nanoplatform enables efficient modulation of bone tumor microenvironment for prostate cancer bone metastasis treatment.

It was difficult to determine the appropriate treatment protocols as there is currently no approved treatment for patients with prostate cancer bone metastasis. The relationship between cancer cells and bone microenvironment, particularly the Sonic hedgehog protein signaling in the bone microenvironment, is instrumental in prostate cancer bone metastasis. The SHH promotes osteoblast maturation and osteoblast maturation, while osteoblast genesis is then obscured by RANKL, which promotes osteoblast maturation and osteoblast. This research finds bone-targeting calcium phosphate lipid hybrid nanoparticles coated with docetaxel and SHH siRNA for PCa bone metastasis treatment. This DDS, which contains a NP-loaded NP, provides an effective way to manage PCa bone metastasis.

Source link: https://europepmc.org/article/MED/35285760


Sonodynamical reversion of immunosuppressive microenvironment in prostate cancer via engineered exosomes.

Prostate cancer responds poorly to standard immunotherapy due to the tumor immunosuppressive microenvironment. Exo Ce6+R848 was designed for simple co-incubation of Ce6 and R848 with HEK 293T cell-derived exosomes. The upregulated expression of CD80 and CD86 demonstrated that ultrasonic irradiation enhanced R848-mediated DCs maturation when Exo Ce6+R848 was engulfed by DCs during Exo Ce6+R848's maturation. The exosome delivery program not only provides a blueprint for coping with the side effects of systemic delivery of Ce6 and R848, but also provides an effective combination regimen of cancer immunotherapy.

Source link: https://europepmc.org/article/MED/35236203


Small extracellular vesicle-mediated ITGB6 siRNA delivery downregulates the αVβ6 integrin and inhibits adhesion and migration of recipient prostate cancer cells.

In metastatic castrate-resistant androgen receptor-negative prostate tumors, transcript levels of ITGB6 have dramatically increased in comparison to androgen receptor-positive prostate tumors. In addition, the integrin protein levels in androgen receptor-negative PrCa patient-derived xenografts are significant higher in comparison to androgen receptor-positive PDXs. The androgen receptor-negative PrCa cells in vitro show high amounts of the V6 integrin relative to androgen receptor-positive PrCa cells. Also, expression of the 6 but not the V subunit in comparison to control cells has decreased according to control cells. Cell adhesion and migration of PrCa cells on an V6-specific substrate, LAP-TGF1, is greatly reduced by treatment with sEVs encapsulating ITGB6 siRNA. Our findings reveal an alternative for targeted targeting of the SV6 integrin in PrCa cells using sEVs encapsulating ITGB6 specific siRNAs.

Source link: https://europepmc.org/article/MED/35188070


Oncologic impact of concomitant prostate cancer characteristics at the time of radical cystoprostatectomy for bladder cancer: a population-based analysis.

The aim of this study was to determine the prognostic value of concomitant prostate cancer of the cancer-specific mortality in the aging patient's papulation with radical cystoprostatectomy. Methods and procedures The SEER database has 1468 patients who were treated with RCP for BCa harboring histopathological PCa findings, as well as histopathological PCa findings. According to PCa risk factors predicting CSM, multiple risk regression tested for potential BCa-CSM discrepancies were adjusted for other cause mortality despite other cause mortality.

Source link: https://europepmc.org/article/MED/35179092


Inhibitory effect of roburic acid in combination with docetaxel on human prostate cancer cells.

Docetaxel is the first-line chemotherapeutic agent for advanced stage prostate cancer, but adverse side effects and drug resistance restrict its clinical success. In this research, the potential synergistic anticancer effect and the root of ROB's pathophysiology were investigated alongside prostate cancer DOC results. The combined effects of ROB and DOC on prostate cancer cells, according to the Mechanistic study, were correlated with reduced NF-B activation, downregulation of Bcl-2, and increased bax monitoring. In addition, we discovered that esomeprazole, a proton pump inhibitor, also increased ROB and DOC's efficacy on prostate cancer cells in acidic culture medium. Since the humidic microclimate is known to stifle the effectiveness of new anticancer therapies, ESOM, ROB, and DOC may be an effective strategy for improving prostate cancer patients's diagnosis.

Source link: https://europepmc.org/article/MED/34986722


GRP78-targeted and doxorubicin-loaded nanodroplets combined with ultrasound: a potential novel theranostics for castration-resistant prostate cancer.

In this research, precise medicine, novel SP94 peptide-modified and doxorubicin-loaded ultrasonic NDs for castration-resistant prostate cancer targeting and therapy were developed in order to achieve the intended goals of precise medicine, novel SP94 peptide-modified and doxorubicin-loaded ultrasonic NDs for castration-resistant prostate cancer diagnosis and therapy. SP94-NDs had greater tumor-specific targeting ability than NDs with conjugation between the SP94 peptide and GRP78-overexpressing 22RV1 cells, relative to blank NDs. SP94-DOX-NDs combined with ultrasound could specifically deliver DOX into 22RV1 cells, resulting in a stronger anticancer effect than both DOX-NDs and DOX. SP94-DOX-NDs, therefore, may be an effective tool for the real-time imaging of tumors as well as prompt drug delivery to tumors.

Source link: https://europepmc.org/article/MED/34985396


Does the type of biopsy used for diagnosis impact subsequent treatment selection in prostate cancer patients?

Targeted biopsy has emerged as an extension to systemic prostate biopsy with improved diagnostic efficiency. The aim of this investigation was to see if biopsy modality had an effect on prostate cancer management. Methods We undertook a retrospective examination of patients with newly diagnosed non-metastatic PCa at our hospital. On multinomial regression results, the biopsy type did not influence AS selection over RP or RT over RP. Conclusions Biopsy technique did not have an effect on patients with new PCa diagnosis.

Source link: https://europepmc.org/article/MED/34983290


The marine factor 3,5-dihydroxy-4-methoxybenzyl alcohol suppresses growth, migration and invasion and stimulates death of metastatic human prostate cancer cells: targeting diverse signaling processes.

Prostate cancer is metastatic cancer, and it is the second leading cause of cancer-related death in men. The present research investigates whether the novel factor 3,5-dihydroxybenzyl alcohol, which was isolated from marine oysters, hinders the growth of metastatic prostate cancer PC-3 or DU-145 cells. In vitro, Culture of DHMBA blocked colony formation and proliferation of PC-3 or DU-145 cells. The immune response of DHMBA on cell proliferation were not triggered by culturing with intracellular signal blockers. Interestingly, the effects of DHMBA on cell proliferation and death were blocked by culturing with an inhibitor of aryl hydrocarbon receptors related to transcriptional regulation. In addition, the DHMBA's environment prevented the growth of reactive oxygen species in PC-3 or DU-145 cells. DHMBA, a novel marine protein, has been shown to inhibit metastatic prostate cancer cells by targeting diverse signaling pathways. This report may lead to a new approach for prostate cancer therapy with DHMBA.

Source link: https://europepmc.org/article/MED/35324521

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions